Study Summary:
A 12-week study of a medicine in subjects with moderate to severe Parkinson’s Disease. There is a 9 month open label extension for those who complete the core study.
Qualified Participants Must:
• Have a diagnosis of Parkinson's Disease (PD), on prior Levodopa therapy for 1 year, with or without dyskinesias, and minimum of 2 hours per day of “off” time
•
Not have a history of repeated strokes or repeated head injury, cognitive impairment or other psychiatric disorder, and cannot have a history of sustained remission of PD
Qualified Participants May Receive:
Study related medical care, study medication, and compensation for time and travel.